Daunorubicin Inj 2 mg per ml, 10 ml: Supply issue
Pfizer have advised us of a supply issue with Daunorubicin inj 2 mg per ml, 10 ml (pharmacode 2325500).
Update 2 May 2021: Resupply date changed to end June 2022.
Reason for the supply issue
Pfizer advises that the issue was caused by increased recent demand combined with a manufacturing issue with the latest batch of daunorubicin.
We understand that stock will run out by mid-May 2022 with resupply expected in end June 2022.
A replacement daunorubicin will be listed in the Schedule from 1 May 2022 and stocks are expected to arrive by 10 May 2022.
This product will be available until Pfizer's daunorubicin product is resupplied.
The alternative product is Daunorubicin Zentiva, 20 mg powder for injection supplied in a 10 vial pack (Pharmacode 2636476). This product is not Medsafe registered. It will need to be supplied under section 29 of the Medicine Act.
Prescribing and supplying a medicine under section 29
Section 29 of the Medicines Act allows for medicines that are not Medsafe approved to be prescribed and supplied to people. The medicine must be prescribed by someone registered with the Medical Council of New Zealand – e.g., doctors.
We know supplying a medicine under section 29 is not ideal. In this case, however, the alternative would be for patients to have no daunorubicin.
We apologise for any inconvenience this causes.
Information for pharmacists
Please note that the Ministry of Health Sector Operations Group will be able to process these claims in May 2022 in the normal claim cycle.
Who to contact
If you have questions about funding for daunorubicin, email firstname.lastname@example.org